A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

MA Geller, S Cooley, PL Judson, R Ghebre, LF Carson… - Cytotherapy, 2011 - Elsevier
Background Natural killer (NK) cells derived from patients with cancer exhibit diminished
cytotoxicity compared with NK cells from healthy individuals. We evaluated the tumor
response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast
cancer Methods Patients underwent a lymphodepleting preparative regimen: fludarabine 25
mg/m 2× 5 doses, cyclophosphamide 60 mg/kg× 2 doses, and, in seven patients, 200 cGy
total body irradiation (TBI) to increase host immune suppression. An NK cell product, from a …